Cargando…

PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells

PURPOSE OF REVIEW: Proprotein convertase subtilisin/kexin type-9 (PCSK9) binds to LDL receptor (LDLR) and targets it for lysosomal degradation in cells. Decreased hepatic clearance of plasma LDL-cholesterol is the primary gauge of PCSK9 activity in humans; however, PCSK9's evolutionary role may...

Descripción completa

Detalles Bibliográficos
Autor principal:	Lagace, Thomas A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2014
Materias:	ATHEROSCLEROSIS: CELL BIOLOGY AND LIPOPROTEINS: Edited by Andrew Newby and Yury Miller
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4166010/ https://www.ncbi.nlm.nih.gov/pubmed/25110901 http://dx.doi.org/10.1097/MOL.0000000000000114

Ejemplares similares

Small entities with large impact: microcalcifications and atherosclerotic plaque vulnerability
por: Hutcheson, Joshua D., et al.
Publicado: (2014)

From genotype to phenotype in human atherosclerosis - recent findings
por: Holdt, Lesca M., et al.
Publicado: (2013)

What does procollagen C-endopeptidase enhancer protein 2 have to do with HDL-cholesteryl ester uptake? Or how I learned to stop worrying and love reverse cholesterol transport?
por: Sorci-Thomas, Mary G., et al.
Publicado: (2015)

Exosomes: emerging roles in communication between blood cells and vascular tissues during atherosclerosis
por: Huber, Heinrich J., et al.
Publicado: (2015)

Association between circulating big endothelin-1 and noncalcified or mixed coronary atherosclerotic plaques
por: Wang, Fang, et al.
Publicado: (2019)

The importance of physiologic ischemia training in preventing the development of atherosclerosis: the role of endothelial progenitor cells in atherosclerotic rabbits
por: Kong, Mingya, et al.
Publicado: (2019)

Non-invasive evaluation of coronary heart disease in patients with chronic kidney disease using photoplethysmography
por: Saritas, Turgay, et al.
Publicado: (2019)

PCSK9 Prosegment Chimera as Novel Inhibitors of LDLR Degradation
por: Luna Saavedra, Yascara Grisel, et al.
Publicado: (2013)

Non-parenchymal hepatic cell lipotoxicity and the coordinated progression of non-alcoholic fatty liver disease and atherosclerosis
por: Peters, Kia M., et al.
Publicado: (2018)

The iterative lipid impact on inflammation in atherosclerosis
por: Kraaijenhof, Jordan M., et al.
Publicado: (2021)

Extracellular matrix: paving the way to the newest trends in atherosclerosis
por: Gialeli, Chrysostomi, et al.
Publicado: (2021)

The role of gut-derived oxidized lipids and bacterial lipopolysaccharide in systemic inflammation and atherosclerosis
por: Wang, Huan, et al.
Publicado: (2022)

Early atherogenesis: new insights from new approaches
por: Scipione, Corey A., et al.
Publicado: (2022)

Characteristics of plaque lipid-associated macrophages and their possible roles in the pathogenesis of atherosclerosis
por: Kim, Kyeongdae, et al.
Publicado: (2022)

Imaging Atherosclerosis
por: Tarkin, Jason M., et al.
Publicado: (2016)

Chelation therapy after the Trial to Assess Chelation Therapy: results of a unique trial
por: Avila, Maria D., et al.
Publicado: (2014)

Trafficking Dynamics of PCSK9-Induced LDLR Degradation: Focus on Human PCSK9 Mutations and C-Terminal Domain
por: Poirier, Steve, et al.
Publicado: (2016)

Andanzas en México
por: Páporov, Yuri
Publicado: (1994)

Hepatocyte Nuclear Factor 1α Plays a Critical Role in PCSK9 Gene Transcription and Regulation by the Natural Hypocholesterolemic Compound Berberine
por: Li, Hai, et al.
Publicado: (2009)

The effect of PCSK9 immunization on the hepatic level of microRNAs associated with the PCSK9/LDLR pathway
por: Ataei, Sarina, et al.
Publicado: (2023)

PCSK9/LDLR System and Rheumatoid Arthritis-Related Atherosclerosis
por: Arida, Aikaterini, et al.
Publicado: (2021)

The cargo receptor SURF4 promotes the efficient cellular secretion of PCSK9
por: Emmer, Brian T, et al.
Publicado: (2018)

The LDLR, APOB, and PCSK9 Variants of Index Patients with Familial Hypercholesterolemia in Russia
por: Meshkov, Alexey, et al.
Publicado: (2021)

Low Density Lipoprotein Binds to Proprotein Convertase Subtilisin/Kexin Type-9 (PCSK9) in Human Plasma and Inhibits PCSK9-mediated Low Density Lipoprotein Receptor Degradation
por: Kosenko, Tanja, et al.
Publicado: (2013)

c-IAP1 Binds and Processes PCSK9 Protein: Linking the c-IAP1 in a TNF-α Pathway to PCSK9-Mediated LDLR Degradation Pathway
por: Xu, Weiming, et al.
Publicado: (2012)

Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblasts
por: Nguyen, My-Anh, et al.
Publicado: (2014)

Dose Effects of Ammonium Perfluorooctanoate on Lipoprotein Metabolism in APOE*3-Leiden.CETP Mice
por: Pouwer, Marianne G, et al.
Publicado: (2019)

In Silico Insights into Protein–Protein Interaction Disruptive Mutations in the PCSK9-LDLR Complex
por: Martin, William R., et al.
Publicado: (2020)

Characterization of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Trafficking Reveals a Novel Lysosomal Targeting Mechanism via Amyloid Precursor-like Protein 2 (APLP2)
por: DeVay, Rachel M., et al.
Publicado: (2013)

17β-Estradiol Inhibits PCSK9-Mediated LDLR Degradation Through GPER/PLC Activation in HepG2 Cells
por: Fu, Wei, et al.
Publicado: (2020)

Whole exome sequencing of familial hypercholesterolaemia patients negative for LDLR/APOB/PCSK9 mutations
por: Futema, Marta, et al.
Publicado: (2014)

LDLR and PCSK9 Are Associated with the Presence of Antiphospholipid Antibodies and the Development of Thrombosis in aPLA Carriers
por: Ochoa, Eguzkine, et al.
Publicado: (2016)

A phenome-wide association study to discover pleiotropic effects of PCSK9, APOB, and LDLR
por: Safarova, Maya S., et al.
Publicado: (2019)

Chronic Mountain Sickness: Clinical Aspects, Etiology, Management, and Treatment
por: Villafuerte, Francisco C., et al.
Publicado: (2016)

Going to Altitude with a Preexisting Psychiatric Condition
por: Hüfner, Katharina, et al.
Publicado: (2019)

Counseling Patients with Chronic Obstructive Pulmonary Disease Traveling to High Altitude
por: Bloch, Konrad E., et al.
Publicado: (2023)

Genetic Variants of LDLR and PCSK9 Associated with Variations in Response to Antihypercholesterolemic Effects of Armolipid Plus with Berberine
por: De Castro-Orós, Isabel, et al.
Publicado: (2016)

A New Strategy for Rapidly Screening Natural Inhibitors Targeting the PCSK9/LDLR Interaction In Vitro
por: Li, Li, et al.
Publicado: (2018)

23,24-Dihydrocucurbitacin B promotes lipid clearance by dual transcriptional regulation of LDLR and PCSK9
por: Li, Hui-hui, et al.
Publicado: (2019)

Heterozygous Ldlr-Deficient Hamster as a Model to Evaluate the Efficacy of PCSK9 Antibody in Hyperlipidemia and Atherosclerosis
por: Wu, Yue, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_sorqmbrvdha35r6ngr6bmecf4l